Company news
Travere Therapeutics, Inc. (NASDAQ:TVTX) news
Travere Therapeutics, Inc. news releases on 6ix. Latest, Jun 8, 2023: Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal…
Press releases — page 3
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 7, 2023
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 30, 2023
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 3, 2023
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
April 30, 2023
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 25, 2023
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
March 31, 2023
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 22, 2023
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
March 13, 2023
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 2, 2023
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 27, 2023
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 16, 2023
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 8, 2023
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 14, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 26, 2022
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 25, 2022
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 19, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 12, 2022
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
August 24, 2022
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 21, 2022
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
August 21, 2022
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 3, 2022
Travere Therapeutics Provides Regulatory Updates on its Development Programs
August 2, 2022
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 27, 2022
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
May 16, 2022
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 15, 2022
Travere Therapeutics Reports First Quarter 2022 Financial Results
May 4, 2022
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 2, 2022
Travere Therapeutics to Report First Quarter 2022 Financial Results
April 27, 2022
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
April 19, 2022
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
April 5, 2022
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
March 20, 2022
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
March 7, 2022
Travere Announces Proposed Convertible Senior Notes Offering
March 7, 2022
Travere Therapeutics to Present at the Barclays Global Healthcare Conference
March 2, 2022
Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
February 27, 2022
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results
February 9, 2022
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 8, 2022
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 9, 2022
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
January 3, 2022
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
December 14, 2021
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
November 1, 2021
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
October 27, 2021
Travere Therapeutics to Report Third Quarter 2021 Financial Results
October 13, 2021
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021
Travere Therapeutics Announces Transition of Chief Medical Officer
October 11, 2021